

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Kyowa Kirin (burosumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Beacon • Brain and Spine Foundation • Brittle Bone Society • Genetic Alliance UK • Metabolic Support UK • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • STEPS • XLH UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Dental Association • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Society for Paediatric Endocrinology and Diabetes • British Society for Rehabilitation Medicine • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • A A H Pharmaceuticals (alphacalcitriol) • Atnahs Pharma UK (calcitriol) • Sigma Pharmaceuticals (alphacalcitriol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England

Final stakeholder list for the appraisal of burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Issue date: February 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

1 of 3

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital • Charles Dent Metabolic Unit, UCLH • Department of Health and Social Care • Leeds Teaching Hospitals NHS Trust • Manchester University Hospitals NHS Foundation Trust, Metabolic Bone Disease Team • NHS England • Northern General Hospital, Metabolic Bone Centre • Nuffield Orthopaedic Centre • Royal National Orthopaedic Hospital • University Hospitals Birmingham NHS Foundation Trust • University Hospitals Bristol, Rheumatology Department • University of Edinburgh Western General Hospital, Rheumatic Diseases Unit • Welsh Government 	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation • Society of Back Pain Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Final stakeholder list for the appraisal of burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Issue date: February 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.